|
1
|
No authors listed: Effects of vinorelbine
on quality of life and survival of elderly patients with advanced
non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine
Italian Study Group. J Natl Cancer Inst. 91:66–72. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gridelli C, Perrone F, Gallo C, et al:
Chemotherapy for elderly patients with advanced non-small-cell lung
cancer: The Multicenter Italian Lung Cancer in the Elderly Study
(MILES) phase III randomized trial. J Natl Cancer Inst. 95:362–372.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gridelli C, Maione P, Illiano A, et al:
Cisplatin plus gemcitabine or vinorelbine for elderly patients with
advanced non small-cell lung cancer: The MILES-2P studies. J Clin
Oncol. 25:4663–4669. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quoix E, Zalcman G, Oster JP, et al:
Carboplatin and weekly paclitaxel doublet chemotherapy compared
with monotherapy in elderly patients with advanced non-small-cell
lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet.
378:1079–1088. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wisnivesky JP, Smith CB, Packer S, et al:
Survival and risk of adverse events in older patients receiving
postoperative adjuvant chemotherapy for resected stages II–IIIA
lung cancer: Observational cohort study. BMJ. 343:d40132011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hainsworth JD, Carrell D, Drengler RL, et
al: Weekly combination chemotherapy with docetaxel and gemcitabine
as first-line treatment for elderly patients and patients with poor
performance status who have extensive-stage small cell lung
carcinoma: A minnie pearl cancer research network phase II trial.
Cancer. 100:2437–2441. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen KS, Neal JW and Wakelee H: Review
of the current targeted therapies for non-small-cell lung cancer.
World J Clin Oncol. 5:576–587. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tam TC, Ho JC, Wong MK, et al: Treatment
outcomes in elderly with advanced-stage non-small cell lung cancer.
Lung. 191:645–654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen YM, Tsai CM, Fan WC, et al: Phase II
randomized trial of erlotinib versus vinorelbine in chemonaive,
advanced, non-small cell lung cancer patients aged 70 years or
older. J Thorac Oncol. 7:412–418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sandler A, Gray R, Perry MC, et al:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ramalingam SS, Dahlberg SE, Langer CJ,
Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH and Johnson
DH: Eastern Cooperative Oncology Group: Outcomes for elderly,
advanced- stage non-small-cell lung cancer patients treated with
bevacizumab in combination with carboplatin and paclitaxel:
analysis of eastern cooperative oncology group trial 4599. J Clin
Oncol. 26:60–65. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leighl NB, Zatloukal P, Mezger J, et al:
Efficacy and safety of bevacizumab-based therapy in elderly
patients with advanced or recurrent nonsquamous non-small cell lung
cancer in the phase III BO17704 study (AVAiL). J Thorac Oncol.
5:1970–1976. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wheatley-Price P, Ding K, Seymour L, Clark
GM and Shepherd FA: Erlotinib for advanced non-small-cell lung
cancer in the elderly: An analysis of the national cancer institute
of Canada clinical trials group study BR.21. J Clin Oncol.
26:2350–2357. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jackman DM, Yeap BY, Lindeman NI, Fidias
P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM,
et al: Phase II clinical trial of chemotherapy-naive patients >
or=70 years of age treated with erlotinib for advanced
non-small-cell lung cancer. J Clin Oncol. 25:760–766. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crinò L, Cappuzzo F, Zatloukal P, Reck M,
Pesek M, Thompson JC, Ford HE, Hirsch FR, Varella-Garcia M,
Ghiorghiu S, et al: Gefitinib versus vinorelbine in
chemotherapy-naive elderly patients with advanced non-small-cell
lung cancer (INVITE): A randomized, phase II study. J Clin Oncol.
26:4253–4260. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Maemondo M, Minegishi Y, Inoue A,
Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T,
Isobe H, et al: First-line gefitinib in patients aged 75 or older
with advanced non-small cell lung cancer harboring epidermal growth
factor receptor mutations: NEJ 003 study. J Thorac Oncol.
7:1417–1422. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takahashi K, Saito H, Hasegawa Y, Ando M,
Yamamoto M, Kojima E, Sugino Y, Kimura T, Yokoyama T, Ogasawara T,
et al: First-line gefitinib therapy for elderly patients with
non-small cell lung cancer harboring EGFR mutation: Central Japan
Lung Study Group 0901. Proc IASLC: abstr P1.11–017. 2013.
|
|
19
|
Fujita S, Katakami N, Masago K, Yoshioka
H, Tomii K, Kaneda T, Hirabayashi M, Kunimasa K, Morizane T and Mio
T: Customized chemotherapy based on epidermal growth factor
receptor mutation status for elderly patients with advanced
non-small-cell lung cancer: A phase II trial. BMC Cancer.
12:1852012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
LeCaera H, Greillierb L, Corre R, Jullian
H, Crequit J, Falchero L, Dujon C, Berard H, Vergnenegre A, Chouaid
C, et al: A multicenter phase II randomized trial of gemcitabine
followed by erlotinib at progression, versus the reverse sequence,
in vulnerable elderly patients with advanced non small-cell lung
cancer selected with a comprehensive geriatric assessment (the GFPC
0505 study). Lung Cancer. 77:97–103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gridelli C, Novello S, Zilembo N, Luciani
A, Favaretto AG, De Marinis F, Genestreti G, Crinò L, Grossi F,
Caffo O, et al: Phase II randomized study of vandetanib plus
gemcitabine or gemcitabine plus placebo as first line treatment of
advanced non small cell lung cancer in elderly patients. J Thorac
Oncol. 9:733–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garrido P, Thatcher N, Crino L, et al:
Safety and efficacy of first-line bevacizumab (Bv) plus
chemotherapy in elderly patients (pts) with advanced or recurrent
non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390).
EJC Suppl. 7:5572009. View Article : Google Scholar
|
|
23
|
Jatoi A: Adjuvant chemotherapy and
targeted therapy in elderly non-small-cell lung cancer patients.
Aging Health. 8:309–316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Socinski MA, Patel JD, Garon EB, Govindan
R, Reynolds CH, Spigel DR, Olsen MR, Liu J, Guba SC and Bonom P: A
phase III study of pemetrexed (Pem) plus carboplatin (Cb) plus
bevacizumab (Bev) followed by maintenance pem plus bev versus
paclitaxel (Pac) plus cb plus bev followed by maintenance bev in
stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC):
Overall and age group results. J Clin Oncol. 31(suppl): abstr 8004.
2013.PubMed/NCBI
|
|
25
|
Schuette W, Nagel S, Schneider CP,
Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke M, Hoeffken G,
Kortsik C and Reck M: 65 plus: A randomized phase III trial of
pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and
carboplatin as first-line treatment for elderly patients with
advanced nonsquamous, non-small cell lung cancer (NSCLC). J Clin
Oncol. 31(suppl): abstr 8013. 2013.
|
|
26
|
Hershman DL, Wright JD, Lim E, Buono DL,
Tsai WY and Neugut AI: Contraindicated use of bevacizumab and
toxicity in elderly patients with cancer. J Clin Oncol.
31:3592–3599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Costanzo R, Piccirillo MC, Sandomenico C,
et al: Gefitinib in non small cell lung cancer. J Biomed
Biotechnol. 2011:8152692011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Schmid-Bindert G and Zhou C:
Erlotinib in the treatment of advanced non-small cell lung cancer:
An update for clinicians. Ther Adv Med Oncol. 4:19–29. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: National Cancer Institute of Canada Clinical Trials
Group: Erlotinib in previously treated non-small-cell lung cancer.
N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thatcher N, Chang A, Parikh P, et al:
Gefitinib plus best supportive care in previously treated patients
with refractory advanced non-small-cell lung cancer: Results from a
randomised, placebo-controlled, multicentre study (Iressa Survival
Evaluation in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim ES, Hirsh V, Mok T, et al: Gefitinib
versus docetaxel in previously treated non-small-cell lung cancer
(INTEREST): A randomised phase III trial. Lancet. 372:1809–1818.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mitsudomi T, Morita S, Yatabe Y, et al:
West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maemondo M, Inoue A, Kobayashi K, et al:
North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tateishi K, Ichiyama T, Hirai K, Agatsuma
T, Koyama S, Hachiya T, Morozumi N, Shiina T and Koizumi T:
Clinical outcomes in elderly patients administered gefitinib as
first-line treatment in epidermal growth factor receptor-mutated
non-small-cell lung cancer: Retrospective analysis in a Nagano lung
cancer research group study. Med Oncol. 30:4502013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Blackhall F, Shaw A, Jänne PA, Kim DW,
Wilner KD, Schnell P, Polli S and Besse B: Crizotinib safety
profile in elderly and non-elderly patients with advanced ALK+
non-small cell lung cancer. Proc IASLC: abstr P1.11–017. 2013.
|
|
36
|
Multicentre randomised phase II trial of
erlotinib versus carboplatin/vinorelbine in elderly patients
(=/> 70 years) with advanced non-small cell lung cancer).
http://clinicaltrials.gov/show/NCT00678964Accessed.
September 19–2014
|
|
37
|
Phase I clinical and pharmacokinetic study
of pazopanib in a population of frail elderly patients according
SIOG criteria. http://clinicaltrials.gov/show/NCT01642017Accessed.
September 19–2014
|
|
38
|
An open label phase I dose escalation
trial of oral BIBF 1120 in combination with intravenous vinorelbine
in elderly patients with advanced non small lung cell cancer -
stage IV (VENUS-1). http://clinicaltrials.gov/show/NCT01684111Accessed.
September 19–2014
|
|
39
|
An open label phase I dose escalation
trial of oral BIBF 1120 in combination with intravenous carboplatin
and vinorelbine in elderly patients with advanced non-small cell
lung cancer - stage IV (VENUS-2). http://clinicaltrials.gov/show/NCT01683682Accessed.
September 19–2014
|
|
40
|
Randomised phase II trial of bevacizumab
(AVASTIN®) in combination with gemcitabine or attenuated doses of
cisplatin and gemcitabine as first-line treatment of elderly
patients with advanced non-squamous non-small cell lung cancer -
EAGLES. http://clinicaltrials.gov/show/NCT01077713Accessed.
September 19–2014
|
|
41
|
Mir O, Blanchet B and Goldwasser F:
Drug-induced effects on erlotinib metabolism. N Engl J Med.
365:379–380. 2011. View Article : Google Scholar : PubMed/NCBI
|
